|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
CA2359244C
(en)
|
1999-01-13 |
2013-10-08 |
Bayer Corporation |
.omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
|
|
DK1478358T3
(da)
|
2002-02-11 |
2013-10-07 |
Bayer Healthcare Llc |
Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
|
|
UY28213A1
(es)
|
2003-02-28 |
2004-09-30 |
Bayer Pharmaceuticals Corp |
Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
|
|
PT1626714E
(pt)
|
2003-05-20 |
2007-08-24 |
Bayer Pharmaceuticals Corp |
Diarilureias para doenças mediadas por pdgfr
|
|
ES2297490T3
(es)
|
2003-07-23 |
2008-05-01 |
Bayer Pharmaceuticals Corporation |
Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones.
|
|
WO2005037198A2
(en)
*
|
2003-10-06 |
2005-04-28 |
Glaxo Group Limited |
Preparation of 1,7-disubstituted azabenzimidazoles as kinase inhibitors
|
|
TW200626155A
(en)
|
2004-09-20 |
2006-08-01 |
Xenon Pharmaceuticals Inc |
Heterocyclic derivatives and their use as therapeutic agents
|
|
TW200626154A
(en)
*
|
2004-09-20 |
2006-08-01 |
Xenon Pharmaceuticals Inc |
Heterocyclic derivatives and their use as therapeutic agents
|
|
CN101083982A
(zh)
|
2004-09-20 |
2007-12-05 |
泽农医药公司 |
用于治疗硬脂酰CoA去饱和酶介导的疾病的杂环衍生物
|
|
CN101084207A
(zh)
|
2004-09-20 |
2007-12-05 |
泽农医药公司 |
杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
|
|
WO2006034279A1
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as therapeutic agents
|
|
BRPI0515478A
(pt)
|
2004-09-20 |
2008-07-22 |
Xenon Pharmaceuticals Inc |
derivados heterocìclicos e seu uso como mediadores de estearoil-coa-desaturase
|
|
AU2005329423A1
(en)
|
2004-09-20 |
2006-09-28 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
|
|
BRPI0611187A2
(pt)
|
2005-06-03 |
2010-08-24 |
Xenon Pharmaceuticals Inc |
derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
|
|
AR056786A1
(es)
*
|
2005-11-10 |
2007-10-24 |
Smithkline Beecham Corp |
Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com
|
|
US7625890B2
(en)
|
2005-11-10 |
2009-12-01 |
Smithkline Beecham Corp. |
Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
|
|
US20080269131A1
(en)
*
|
2005-11-10 |
2008-10-30 |
Smithkline Beecham Corporation |
Inhibitors of Akt Activity
|
|
WO2007058852A2
(en)
*
|
2005-11-10 |
2007-05-24 |
Smithkline Beecham Corporation |
Inhibitors of akt activity
|
|
US20080063637A1
(en)
*
|
2006-05-19 |
2008-03-13 |
The Trustees Of Tufts College |
Regulation of oncogenesis by Akt-specific isoforms
|
|
WO2008063853A2
(en)
*
|
2006-11-21 |
2008-05-29 |
Smithkline Beecham (Cork) Limited |
Cancer treatment method
|
|
WO2008121685A1
(en)
*
|
2007-03-28 |
2008-10-09 |
Smithkline Beecham Corporation |
Methods of use for inhibitors of akt activity
|
|
EP2286232B1
(en)
*
|
2008-05-16 |
2012-02-29 |
Cellzome Ag |
Methods for the identification of parp interacting molecules and for purification of parp proteins
|
|
SG181947A1
(en)
|
2009-12-30 |
2012-07-30 |
Arqule Inc |
Substituted imidazopyridinyl-aminopyridine compounds
|
|
KR20130009978A
(ko)
*
|
2010-02-26 |
2013-01-24 |
가부시키가이샤 한도오따이 에네루기 켄큐쇼 |
반도체 소자의 제조 방법 및 성막 장치
|
|
KR101419999B1
(ko)
*
|
2011-03-31 |
2014-08-12 |
건국대학교 산학협력단 |
Ａｋｔ 음성 조절제로서의 Ｈａｄｅｓ의 용도
|
|
SG194045A1
(en)
|
2011-04-01 |
2013-11-29 |
Genentech Inc |
Combinations of akt inhibitor compounds and abiraterone, and methods of use
|
|
CA2837727C
(en)
|
2011-06-24 |
2019-12-03 |
Arqule, Inc. |
Substituted imidazopyridinyl-aminopyridine compounds
|
|
US8815854B2
(en)
|
2011-06-24 |
2014-08-26 |
Arqule, Inc. |
Substituted imidazopyridinyl compounds
|
|
US9388126B2
(en)
|
2012-07-19 |
2016-07-12 |
Drexel University |
Sigma receptor ligands and methods of modulating cellular protein homeostasis using same
|
|
BR112015022923A2
(pt)
|
2013-03-15 |
2017-07-18 |
Syngenta Participations Ag |
derivados de imidazopiridina microbicidamente ativos
|
|
JP6197125B2
(ja)
*
|
2014-02-05 |
2017-09-13 |
ブイエム オンコロジー リミテッド ライアビリティ カンパニー |
化合物の組成物およびその使用
|
|
WO2016038143A1
(en)
*
|
2014-09-12 |
2016-03-17 |
Syngenta Participations Ag |
Microbiocidal 4-(imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3- amine compounds having an oxime group in position 7
|
|
HUE056777T2
(hu)
|
2016-12-22 |
2022-03-28 |
Amgen Inc |
Benzizotiazol-, izotiazolo[3,4-b]piridin-, kinazolin-, ftálazin-, pirido[2,3-d]piridazin- és pirido[2,3-d]pirimidin-származékok mint KRAS G12C inhibitorok tüdõ-, hasnyálmirigy- vagy vastagbélrák kezelésére
|
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
|
MA50077A
(fr)
|
2017-09-08 |
2020-07-15 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
|
US11117870B2
(en)
|
2017-11-01 |
2021-09-14 |
Drexel University |
Compounds, compositions, and methods for treating diseases
|
|
CA3098574A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
MX2020011582A
(es)
|
2018-05-04 |
2020-11-24 |
Amgen Inc |
Inhibidores de kras g12c y metodos para su uso.
|
|
MA52564A
(fr)
|
2018-05-10 |
2021-03-17 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
|
MA52765A
(fr)
|
2018-06-01 |
2021-04-14 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
|
AU2019284472B2
(en)
|
2018-06-11 |
2024-05-30 |
Amgen Inc. |
KRAS G12C inhibitors for treating cancer
|
|
CA3100390A1
(en)
|
2018-06-12 |
2020-03-12 |
Amgen Inc. |
Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer
|
|
JP2022512706A
(ja)
|
2018-10-16 |
2022-02-07 |
エフ．ホフマン－ラ ロシュ アーゲー |
眼科におけるＡｋｔ阻害剤の使用
|
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
|
|
MX2021005700A
(es)
|
2018-11-19 |
2021-07-07 |
Amgen Inc |
Inhibidores de kras g12c y metodos de uso de los mismos.
|
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
|
|
MX2021007156A
(es)
|
2018-12-20 |
2021-08-16 |
Amgen Inc |
Inhibidores de kif18a.
|
|
US20220002311A1
(en)
|
2018-12-20 |
2022-01-06 |
Amgen Inc. |
Kif18a inhibitors
|
|
CA3123227A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
|
EP3897855B1
(en)
|
2018-12-20 |
2023-06-07 |
Amgen Inc. |
Kif18a inhibitors
|
|
US20230148450A9
(en)
|
2019-03-01 |
2023-05-11 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
|
JP2022522778A
(ja)
|
2019-03-01 |
2022-04-20 |
レボリューション メディシンズ インコーポレイテッド |
二環式ヘテロシクリル化合物及びその使用
|
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
|
US11236091B2
(en)
|
2019-05-21 |
2022-02-01 |
Amgen Inc. |
Solid state forms
|
|
JP2022542319A
(ja)
|
2019-08-02 |
2022-09-30 |
アムジエン・インコーポレーテツド |
Ｋｉｆ１８ａ阻害剤
|
|
CN114269731A
(zh)
|
2019-08-02 |
2022-04-01 |
美国安进公司 |
Kif18a抑制剂
|
|
WO2021026098A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
|
MX2022001302A
(es)
|
2019-08-02 |
2022-03-02 |
Amgen Inc |
Inhibidores de kif18a.
|
|
US20220402916A1
(en)
|
2019-09-18 |
2022-12-22 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
|
MX2022004656A
(es)
|
2019-10-24 |
2022-05-25 |
Amgen Inc |
Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
|
|
CN114867726B
(zh)
|
2019-10-28 |
2023-11-28 |
默沙东有限责任公司 |
Kras g12c突变体的小分子抑制剂
|
|
US20230023023A1
(en)
|
2019-10-31 |
2023-01-26 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
|
JP2022553859A
(ja)
|
2019-11-04 |
2022-12-26 |
レボリューション メディシンズ インコーポレイテッド |
Ｒａｓ阻害剤
|
|
CA3159561A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2021091967A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20210139517A1
(en)
|
2019-11-08 |
2021-05-13 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
|
US20230192681A1
(en)
|
2019-11-14 |
2023-06-22 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
|
MX2022005726A
(es)
|
2019-11-14 |
2022-06-09 |
Amgen Inc |
Sintesis mejorada del compuesto inhibidor de g12c de kras.
|
|
CN114980976A
(zh)
|
2019-11-27 |
2022-08-30 |
锐新医药公司 |
共价ras抑制剂及其用途
|
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
|
AU2021206217A1
(en)
|
2020-01-07 |
2022-09-01 |
Revolution Medicines, Inc. |
SHP2 inhibitor dosing and methods of treating cancer
|
|
US20230174518A1
(en)
|
2020-04-24 |
2023-06-08 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
|
US20230181536A1
(en)
|
2020-04-24 |
2023-06-15 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
|
BR112022025550A2
(pt)
|
2020-06-18 |
2023-03-07 |
Revolution Medicines Inc |
Métodos para retardar, prevenir e tratar resistência adquirida aos inibidores de ras
|
|
EP4183395A4
(en)
|
2020-07-15 |
2024-07-24 |
Taiho Pharmaceutical Co Ltd |
PYRIMIDINE COMPOUND-CONTAINING COMBINATION FOR USE IN TUMOR TREATMENT
|
|
MX2023002248A
(es)
|
2020-09-03 |
2023-05-16 |
Revolution Medicines Inc |
Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
|
|
CA3194067A1
(en)
|
2020-09-15 |
2022-03-24 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TW202241885A
(zh)
|
2020-12-22 |
2022-11-01 |
大陸商上海齊魯銳格醫藥研發有限公司 |
Ｓｏｓ１抑制劑及其用途
|
|
AR125787A1
(es)
|
2021-05-05 |
2023-08-16 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
WO2022235866A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
PE20240088A1
(es)
|
2021-05-05 |
2024-01-16 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
WO2022250170A1
(en)
|
2021-05-28 |
2022-12-01 |
Taiho Pharmaceutical Co., Ltd. |
Small molecule inhibitors of kras mutated proteins
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
TW202340214A
(zh)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
做為shp2抑制劑之吡唑并吡𠯤化合物
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|
|
WO2024206858A1
(en)
|
2023-03-30 |
2024-10-03 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
WO2024211712A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
WO2024211663A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|